ALRX - Alpharx Inc - Page 4

Good Volume today and the Ask seems to be holding.  However, we need more buying interest.  Hopefully we get a corporate update soon as to how the product pipeline is going and move into China.  We might have to wait until mid August for the 10-Q to be released.

Good Volume again.  It is holding steady but, don't see the buying interest to move up.

Good volume this week and the ask is holding nicely.  Need some buying interest.  Would also like to see an update on Indaflex and GAI-122:

From last Form 10-Q "clinical trial application with the China State Food and Drug Association (“SFDA”) in order to begin human trials in China. These preparations are proceeding on schedule."

May have to wait until mid August for the next Form 10-Q

There is a recent Corporate Fact sheet

Still holding up on the ask and good volume.  It was nice to see the bid at .05 and large size order.

However, once the trades went through no other market makers stepped up to hold it there.

Ask held up again this week.  Not as much volume today at least the low bids didn't win out.

Something interesting in their Investors Fact Sheet:  "AlphaRx Plans to List Subsidiary"

I didn't notice this before.

Anyone been on otcmarkets for quotes the level II is gone now???

Form 10-Q Released

Good Volume this week and at least it finished ok compared to the rest of the market.

Alpharx Income Statement

Considering the overall market it is good to see we held up.

AlphaRX Aug 2011 Insider Purchase Transactions:

LEE MAN CHING 400,000 shares at .05

MOORE KEITH FORD 400,000 shares at .05

MILROY JOHN DAVID 400,000 shares at .05

Quote:

Originally Posted by jackfree 

AlphaRX Aug 2011 Insider Purchase Transactions:

LEE MAN CHING 400,000 shares at .05

MOORE KEITH FORD 400,000 shares at .05

MILROY JOHN DAVID 400,000 shares at .05

 

That's good news.  They'll probably be setting up a pump soon.

Also the latest info is on their Investors Fact Sheet

Last I heard they were in China outsourcing research and awaiting results.

Head Office:
AlphaRx Inc.
19/F, Two International
Finance Centre
8 Finance Street
Central, Hong Kong
Tel: (852) 2251-1927
Fax: (852) 3020-0362
info@AlphaRx.com

AlphaRx entered into a Security Agreement with certain investors for $1,320,082.99 and US$62,594.02

Form 8-K for ALPHARX INC

22-Aug-2011

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Crazy Volume day and price swings, I thought it would hold up but, someone dumped at the end.

At least someone stepped up to recover the price.  I would still like to hear from the company.  Maybe in the next couple of weeks after everyone is back in work mode after Labor day.

Form 8-K for ALPHARX INC

6-Sep-2011

Entry into a Material Definitive Agreement

It is good to see that they only have to pay Grand Eastern Financial Group  a finders fee if the deal actually goes through and for only 5%.  I see many other companies just dilute and pay these advisors in shares that end up getting dumped right after and drop the share price.

AlphaRx Provides Corporate Update

HONG KONG, September 12 /PRNewswire - AlphaRx Inc. (OTC BB:ALRX.OB) is pleased to announce the following Corporate update:

Product Development Update

On July 5, 2011 the Board and management adopted a new business plan that the Company believes will improve the Company’s performance. The new business plan narrows the Company’s focus to developing and commercializing 2 existing product candidates “Indaflex” and “ARX8203” internally, for the pain market.

Indaflex, our flagship product in Mexico, is currently bringing in a royalties of $10,000 per month and is ramping up to $15,000 per month. In addition to Mexico, we are preparing to registering Indaflex in Portugal in conjunction with Andromaco Pharma, Mexico. We have received a proposal from Formifarma, an experienced regulatory firm based in Lisbon, Portugal and we are currently reviewing these options. Other EU countries will follow and the potential annual royalty can be projected at over $12 million from EU countries.
 
With an estimate of around $100-200 million for Gout therapy alone, ARX8203 becomes the near term driver for AlphaRx and also our most exciting product opportunity. We are proposing to conduct an efficacy and safety trial on approximately 90 Gout patients.
 
Another potential blockbuster is GAI-122 for the China Market, as China reports more patients with stroke than anywhere else in the world. The total market potential for GAI-122 in China is approximately $1.68 billion. GAI-122 is being developed by our partner Gaia BioPharma under a licensing agreement.
 
Corporate Development Update

We have completed a small private placement of $100,000 of which $60,000 was placed to our CEO and directors; the funds will be used for general working capital. We have converted all short term demand loans to term loans with maturity on December 21, 2013.  We have recently engaged various professional firms to provide certain services and advice that we strongly believe will increase shareholder value. We are exploring various growth strategies including diversifying into other fast growing health care related businesses and we are evaluating acquisition opportunities that we believe could provide substantial earnings to the Company in a short period of time.

Decent volume and nice pop at the end of the day.

Much better day.  I was a little worried after Friday.  However, the market is fickle and a big down day scares people and then a big up day gives them confidence.